|
Natural advantages
in biosecurity,
biopurity, fertile
agricultural land
and clean
temperate waters... |
 |
|
Opportunities
Biotechnology Opportunities
- Agribiotech
- Marine biotech
- Human health
Tasmania’s capability in the biotechnology sector has evolved from natural advantages in biosecurity, biopurity, fertile agricultural land and clean temperate waters. Several biotech businesses are growing rapidly and large international pharmaceutical companies such as Johnson & Johnson and GlaxoSmithKline have interests in the state.
Tasmania has scientific expertise in niche areas of marine, agricultural and human health biotechnology. Our world-class science facilities and research capabilities set the scene for a globally competitive future for the state in several key biotech sub-sectors.
Agribiotech - Opportunities are being identified for high-value extract crops. Particularly poppies, pyrethrum and therapeutic oils.
Marine biotechnology - Tasmania’s geographic positioning establishes the state as a gateway to the largely untapped and unique ecology of the Antarctic and southern waters. The marine biotechnology sector is backed by a highly concentrated and well-resourced marine research community. Tasmania is home to the largest group of marine science organisations in the southern hemisphere.
Human health biotechnology - Tasmania has some distinctive demographic advantages. The state has a relatively stable, contained population stemming from a small number of founder families, which provides a unique environment for genetic research.
 Education opportunities - The comprehensive nature of the University of Tasmania’s Bachelor of Biotechnology course allows students to gain knowledge and skill in a vast array of disciplines.
The opportunities for post-graduate study across institutions are many, with research students working with both the University of Tasmania and CSIRO Marine Research.
Click here to download Tasmania's Biotechnology Strategy
Related Links:Science and Technology Industry Council Biotechnology Industry Biotechnology Strategy
|
